| 2 |
TAAR1 agonists vs. placebo in adults with
schizophrenia |
Overall symptoms (PANSS total) |
4-6 weeks |
N=4 n=1291; SMD=0.15, 95%CI: -0.05, 0.34;
tau2=0.0247 |
All studies had overall low risk of bias |
All eligible studies had usable data |
No clear indication of indirectness |
Two phase III trials conducted during COVID-19, which
could be associated with factors assocaited with increased placebo
effects and smaller effect sizes |
| 1 |
TAAR1 agonists vs. placebo in Parkinson Disease
Psychosis |
Overall symptoms (NPI) |
6 weeks |
N=1 n=37; SMD=-0.28, 95%CI: -0.95, 0.38 |
1 study with overall high risk of bias |
1 eligible study with usable data |
No clear indication of indirectness |
No clear indication of other biases |
| 27 |
TAAR1 agonists vs. placebo in adults with
schizophrenia |
Response to treatment (≥50% or ≥20% reduction in PANSS
total) |
4-6 weeks |
N=4 n=1357; 23.7% vs. 18.7%, OR=1.35, 95%CI: 0.86,
2.12; tau2=0.1085 |
All studies had overall low risk of bias |
All eligible studies had usable data |
No clear indication of indirectness |
Two phase III trials conducted during COVID-19, which
could be associated with factors assocaited with increased placebo
effects and smaller effect sizes |
| 26 |
TAAR1 agonists vs. placebo in Parkinson Disease
Psychosis |
Response to treatment (≥50% in SAPS-PD) |
6 weeks |
N=1 n=39; 24% vs. 21.4%, OR=1.16, 95%CI: 0.24,
5.58 |
1 study with an overall low risk of bias |
1 eligible study with usable data |
No clear indication of indirectness |
No clear indication of other biases |
| 5 |
TAAR1 agonists vs. placebo in adults with
schizophrenia |
Positive symptoms (PANSS positive subscale/factor) |
4 weeks |
N=2 n=399; SMD=0.23, 95%CI: 0.03, 0.43; tau2=0 |
All studies had overall low risk of bias |
50% of eligible studies and 28.9% of participants had
usable data |
No clear indication of indirectness |
No clear indication of other biases |
| 4 |
TAAR1 agonists vs. placebo in Parkinson Disease
Psychosis |
Positive symptoms (SAPS-PD) |
6 weeks |
N=1 n=38; SMD=0.14, 95%CI: -0.52, 0.8 |
1 study with overall high risk of bias |
1 eligible study with usable data |
No clear indication of indirectness |
No clear indication of other biases |
| 7 |
TAAR1 agonists vs. placebo in adults with
schizophrenia |
Negative symptoms (PANSS negative subscale/factor) |
4 weeks |
N=2 n=399; SMD=0.23, 95%CI: -0.01, 0.48;
tau2=0.0102 |
All studies had overall low risk of bias |
50% of eligible studies and 28.9% of participants had
usable data |
No clear indication of indirectness |
No clear indication of other biases |
| 10 |
TAAR1 agonists vs. placebo in adults with
schizophrenia |
Depressive symptoms (PANSS anxiety/depression
factor) |
4 weeks |
N=2 n=399; SMD=0.17, 95%CI: -0.06, 0.39;
tau2=0.0042 |
All studies had overall low risk of bias |
50% of eligible studies and 28.9% of participants had
usable data |
No clear indication of indirectness |
No clear indication of other biases |
| 9 |
TAAR1 agonists vs. placebo in Parkinson Disease
Psychosis |
Cognitive impairment (MMSE) |
6 weeks |
N=1 n=37; SMD=-0.51, 95%CI: -1.18, 0.17 |
1 study with overall high risk of bias |
1 eligible study with usable data |
No clear indication of indirectness |
No clear indication of other biases |
| 14 |
TAAR1 agonists vs. placebo in any eligible
population |
Dropouts due to any reason |
4-6 weeks |
N=5 n=1396; 22.9% vs. 19.6%, OR=1.22, 95%CI: 0.93, 1.6;
tau2=0 |
All studies had overall low risk of bias |
83.3% of eligible studies and 90.1% of participants had
usable data |
80% studies and 97.2% participants with
schizophrenia |
No clear indication of other biases |
| 16 |
TAAR1 agonists vs. placebo in any eligible
population |
Dropouts due to any reason |
1 day |
N=2 n=93; 11.7% vs. 4.7%, OR=2.67, 95%CI: 0.48,
14.8 |
All studies had overall low risk of bias |
16.7% of eligible studies and 14.9% of participants had
usable data |
0% studies and 0% participants with schizophrenia |
No clear indication of other biases |
| 18 |
TAAR1 agonists vs. placebo in any eligible
population |
Dropouts due to adverse events |
4-6 weeks |
N=3 n=497; 8.1% vs. 7.1%, OR=1.15, 95%CI: 0.58, 2.29;
tau2=0 |
All studies had overall low risk of bias |
50% of eligible studies and 32.1% of participants had
usable data |
66.7% studies and 92.2% participants with
schizophrenia |
No clear indication of other biases |
| 20 |
TAAR1 agonists vs. placebo in any eligible
population |
Dropouts due to adverse events |
1 day |
N=3 n=161; 0.5% vs. 1.6%, OR=0.33, 95%CI: 0.02,
5.72 |
66.7% had overall low risk of bias |
25% of eligible studies and 25.7% of participants had
usable data |
33.3% studies and 42.2% participants with
schizophrenia |
No clear indication of other biases |
| 22 |
TAAR1 agonists vs. placebo in any eligible
population |
Any adverse event |
4-6 weeks |
N=3 n=497; 48.7% vs. 54.6%, OR=0.79, 95%CI: 0.54, 1.15;
tau2=0 |
All studies had overall low risk of bias |
50% of eligible studies and 32.1% of participants had
usable data |
66.7% studies and 92.2% participants with
schizophrenia |
No clear indication of other biases |
| 24 |
TAAR1 agonists vs. placebo in any eligible
population |
Any adverse event |
1 day to 2 weeks |
N=4 n=177; 52.3% vs. 11.4%, OR=8.49, 95%CI: 1.73,
41.66; tau2=1.7741 |
75% had overall low risk of bias |
33.3% of eligible studies and 28.3% of participants had
usable data |
25% studies and 38.4% participants with
schizophrenia |
No clear indication of other biases |
| 65 |
TAAR1 agonists vs. placebo in any eligible
population |
Serious adverse events |
4-6 weeks |
N=3 n=497; 2.8% vs. 2.7%, OR=1.01, 95%CI: 0.32, 3.21;
tau2=0 |
All studies had overall low risk of bias |
50% of eligible studies and 32.1% of participants had
usable data |
66.7% studies and 92.2% participants with
schizophrenia |
No clear indication of other biases |
| 67 |
TAAR1 agonists vs. placebo in any eligible
population |
Serious adverse events |
1 day to 2 weeks |
N=4 n=177; 4.6% vs. 1.6%, OR=3.02, 95%CI: 0.36, 25.76;
tau2=0 |
75% had overall low risk of bias |
33.3% of eligible studies and 28.3% of participants had
usable data |
25% studies and 38.4% participants with
schizophrenia |
No clear indication of other biases |
| 61 |
TAAR1 agonists vs. placebo in any eligible
population |
Mortality due to any cause |
4-6 weeks |
N=3 n=497; 3% vs. 1%, OR=3.15, 95%CI: 0.13, 78.11 |
All studies had overall low risk of bias |
50% of eligible studies and 32.1% of participants had
usable data |
66.7% studies and 92.2% participants with
schizophrenia |
No clear indication of other biases |
| 63 |
TAAR1 agonists vs. placebo in any eligible
population |
Mortality due to any cause |
1 day to 2 weeks |
N=4 n=177; not estimable effect size 0 events in both
arms |
All studies had overall low risk of bias |
33.3% of eligible studies and 28.3% of participants had
usable data |
25% studies and 38.4% participants with
schizophrenia |
No clear indication of other biases |
| 45 |
TAAR1 agonists vs. placebo in any eligible
population |
Nausea/vomitting |
4-6 weeks |
N=3 n=497; 3.9% vs. 4.4%, OR=0.88, 95%CI: 0.25, 3.15;
tau2=0.4981 |
All studies had overall low risk of bias |
50% of eligible studies and 32.1% of participants had
usable data |
66.7% studies and 92.2% participants with
schizophrenia |
No clear indication of other biases |
| 47 |
TAAR1 agonists vs. placebo in any eligible
population |
Nausea/vomitting |
1 day |
N=3 n=161; 19.5% vs. 1.6%, OR=15.14, 95%CI: 3.71,
61.75; tau2=0 |
66.7% had overall low risk of bias |
25% of eligible studies and 25.7% of participants had
usable data |
33.3% studies and 42.2% participants with
schizophrenia |
No clear indication of other biases |
| 12 |
TAAR1 agonists vs. placebo in any eligible
population |
Weight (kg) |
4 weeks |
N=1 n=245; MD=0.4, 95%CI: -0.13, 0.93 |
1 study with an overall low risk of bias |
16.7% of eligible studies and 15.8% of participants had
usable data |
No clear indication of indirectness |
No clear indication of other biases |
| 59 |
TAAR1 agonists vs. placebo in any eligible
population |
Weight increased (≥7% increase or any cutoff) |
4 weeks |
N=2 n=458; 1.1% vs. 1%, OR=1.04, 95%CI: 0.17, 6.47;
tau2=0 |
All studies had overall low risk of bias |
33.3% of eligible studies and 29.5% of participants had
usable data |
No clear indication of indirectness |
No clear indication of other biases |
| 13 |
TAAR1 agonists vs. placebo in any eligible
population |
Prolactin levels (ng/ml) |
4 weeks |
N=1 n=227; MD=-0.58, 95%CI: -7.87, 6.7 |
1 study with an overall low risk of bias |
16.7% of eligible studies and 14.6% of participants had
usable data |
No clear indication of indirectness |
No clear indication of other biases |
| 52 |
TAAR1 agonists vs. placebo in any eligible
population |
Prolactin elevation (any cutoff) |
1 day |
N=1 n=24; not estimable effect size 0 events in both
arms |
1 study with an overall low risk of bias |
8.3% of eligible studies and 3.8% of participants had
usable data |
0% studies and 0% participants with schizophrenia |
No clear indication of other biases |
| 58 |
TAAR1 agonists vs. placebo in any eligible
population |
Extrapyramidal symptoms |
4 weeks |
N=1 n=245; 3.3% vs. 3.2%, OR=1.04, 95%CI: 0.25,
4.27 |
1 study with an overall low risk of bias |
16.7% of eligible studies and 15.8% of participants had
usable data |
No clear indication of indirectness |
No clear indication of other biases |
| 57 |
TAAR1 agonists vs. placebo in any eligible
population |
Akathisia |
4 weeks |
N=1 n=245; 1.2% vs. 0.4%, OR=3.15, 95%CI: 0.13,
78.11 |
1 study with an overall low risk of bias |
16.7% of eligible studies and 15.8% of participants had
usable data |
No clear indication of indirectness |
No clear indication of other biases |
| 35 |
TAAR1 agonists vs. placebo in any eligible
population |
Agitation |
4 weeks |
N=2 n=458; 5.5% vs. 4.2%, OR=1.35, 95%CI: 0.53, 3.43;
tau2=0 |
All studies had overall low risk of bias |
33.3% of eligible studies and 29.5% of participants had
usable data |
No clear indication of indirectness |
No clear indication of other biases |
| 31 |
TAAR1 agonists vs. placebo in any eligible
population |
Anxiety |
4 weeks |
N=2 n=458; 2.6% vs. 7.6%, OR=0.32, 95%CI: 0.12, 0.85;
tau2=0 |
All studies had overall low risk of bias |
33.3% of eligible studies and 29.5% of participants had
usable data |
No clear indication of indirectness |
No clear indication of other biases |
| 33 |
TAAR1 agonists vs. placebo in any eligible
population |
Anxiety |
1 day |
N=1 n=69; not estimable effect size 0 events in both
arms |
1 study with an overall low risk of bias |
8.3% of eligible studies and 11% of participants had
usable data |
0% studies and 0% participants with schizophrenia |
No clear indication of other biases |
| 49 |
TAAR1 agonists vs. placebo in any eligible
population |
Sedation |
4-6 weeks |
N=2 n=284; 8.1% vs. 7.2%, OR=1.14, 95%CI: 0.44, 3;
tau2=0 |
All studies had overall low risk of bias |
33.3% of eligible studies and 18.3% of participants had
usable data |
50% studies and 86.3% participants with
schizophrenia |
No clear indication of other biases |
| 50 |
TAAR1 agonists vs. placebo in any eligible
population |
Sedation |
1 day |
N=2 n=93; 40.6% vs. 8.3%, OR=7.54, 95%CI: 2.56, 22.22;
tau2=0 |
All studies had overall low risk of bias |
16.7% of eligible studies and 14.9% of participants had
usable data |
0% studies and 0% participants with schizophrenia |
No clear indication of other biases |
| 55 |
TAAR1 agonists vs. placebo in any eligible
population |
Insomnia |
4 weeks |
N=2 n=458; 4.7% vs. 4.8%, OR=0.98, 95%CI: 0.07, 13.43;
tau2=2.8647 |
All studies had overall low risk of bias |
33.3% of eligible studies and 29.5% of participants had
usable data |
No clear indication of indirectness |
No clear indication of other biases |
| 37 |
TAAR1 agonists vs. placebo in any eligible
population |
Headache |
4 weeks |
N=2 n=458; 7.9% vs. 9%, OR=0.86, 95%CI: 0.43, 1.69;
tau2=0 |
All studies had overall low risk of bias |
33.3% of eligible studies and 29.5% of participants had
usable data |
No clear indication of indirectness |
No clear indication of other biases |
| 39 |
TAAR1 agonists vs. placebo in any eligible
population |
Headache |
1 day |
N=1 n=69; 11.5% vs. 20.6%, OR=0.5, 95%CI: 0.13,
1.89 |
1 study with an overall low risk of bias |
8.3% of eligible studies and 11% of participants had
usable data |
0% studies and 0% participants with schizophrenia |
No clear indication of other biases |
| 69 |
TAAR1 agonists vs. placebo in any eligible
population |
QTc interval (msec) |
1 day |
N=1 n=62; MD=1.25, 95%CI: -2.87, 5.37 |
1 study with overall some concerns in risk of bias |
8.3% of eligible studies and 9.9% of participants had
usable data |
No clear indication of indirectness |
No clear indication of other biases |
| 53 |
TAAR1 agonists vs. placebo in any eligible
population |
QTc prolongation (any cutoff) |
4 weeks |
N=1 n=245; not estimable effect size 0 events in both
arms |
1 study with an overall low risk of bias |
16.7% of eligible studies and 15.8% of participants had
usable data |
No clear indication of indirectness |
No clear indication of other biases |
| 54 |
TAAR1 agonists vs. placebo in any eligible
population |
QTc prolongation (any cutoff) |
1 day |
N=2 n=92; 8.1% vs. 1.6%, OR=5.32, 95%CI: 0.6,
46.78 |
50% had overall low risk of bias |
16.7% of eligible studies and 14.7% of participants had
usable data |
50% studies and 73.9% participants with
schizophrenia |
No clear indication of other biases |
| 41 |
TAAR1 agonists vs. placebo in any eligible
population |
Hypotension |
6 weeks |
N=1 n=39; 52.4% vs. 78.6%, OR=0.3, 95%CI: 0.07,
1.32 |
1 study with an overall low risk of bias |
16.7% of eligible studies and 2.5% of participants had
usable data |
0% studies and 0% participants with schizophrenia |
No clear indication of other biases |
| 42 |
TAAR1 agonists vs. placebo in any eligible
population |
Dizziness |
6 weeks |
N=1 n=39; 16% vs. 7.1%, OR=2.48, 95%CI: 0.25,
24.65 |
1 study with an overall low risk of bias |
16.7% of eligible studies and 2.5% of participants had
usable data |
0% studies and 0% participants with schizophrenia |
No clear indication of other biases |
| 43 |
TAAR1 agonists vs. placebo in any eligible
population |
Dizziness |
1 day |
N=2 n=137; 19.9% vs. 3.5%, OR=6.89, 95%CI: 1.98, 23.92;
tau2=0 |
50% had overall low risk of bias |
16.7% of eligible studies and 21.9% of participants had
usable data |
50% studies and 49.6% participants with
schizophrenia |
No clear indication of other biases |
| 29 |
TAAR1 agonists vs. placebo in any eligible
population |
Anticholinergic symptom |
1 day |
N=1 n=69; 15.3% vs. 1.4%, OR=12.44, 95%CI: 0.66,
234.38 |
1 study with an overall low risk of bias |
8.3% of eligible studies and 11% of participants had
usable data |
0% studies and 0% participants with schizophrenia |
No clear indication of other biases |
| 3 |
TAAR1 agonists vs. antipsychotics in adults with
schizophrenia |
Overall symptoms (PANSS total) |
4 weeks |
N=1 n=156; SMD=-0.53, 95%CI: -0.86, -0.2 |
1 study with an overall low risk of bias |
1 eligible study with usable data |
No clear indication of indirectness |
No clear indication of other biases |
| 28 |
TAAR1 agonists vs. antipsychotics in adults with
schizophrenia |
Response to treatment (≥50% or ≥20% reduction in PANSS
total) |
4 weeks |
N=1 n=214; 7.9% vs. 13.5%, OR=0.55, 95%CI: 0.22,
1.35 |
1 study with an overall low risk of bias |
1 eligible study with usable data |
No clear indication of indirectness |
No clear indication of other biases |
| 6 |
TAAR1 agonists vs. antipsychotics in adults with
schizophrenia |
Positive symptoms (PANSS positive subscale/factor) |
4 weeks |
N=1 n=156; SMD=-0.55, 95%CI: -0.89, -0.22 |
1 study with an overall low risk of bias |
1 eligible study with usable data |
No clear indication of indirectness |
No clear indication of other biases |
| 8 |
TAAR1 agonists vs. antipsychotics in adults with
schizophrenia |
Negative symptoms (PANSS negative subscale/factor) |
4 weeks |
N=1 n=156; SMD=-0.13, 95%CI: -0.46, 0.19 |
1 study with an overall low risk of bias |
1 eligible study with usable data |
No clear indication of indirectness |
No clear indication of other biases |
| 11 |
TAAR1 agonists vs. antipsychotics in adults with
schizophrenia |
Depressive symptoms (PANSS anxiety/depression
factor) |
4 weeks |
N=1 n=156; SMD=-0.23, 95%CI: -0.56, 0.1 |
1 study with an overall low risk of bias |
1 eligible study with usable data |
No clear indication of indirectness |
No clear indication of other biases |
| 15 |
TAAR1 agonists vs. antipsychotics in any eligible
population |
Dropouts due to any reason |
4 weeks |
N=1 n=214; 22.9% vs. 18.9%, OR=1.27, 95%CI: 0.63,
2.56 |
1 study with an overall low risk of bias |
16.7% of eligible studies and 13.8% of participants had
usable data |
No clear indication of indirectness |
No clear indication of other biases |
| 17 |
TAAR1 agonists vs. antipsychotics in any eligible
population |
Dropouts due to any reason |
1 day |
N=1 n=71; 14.3% vs. 5.6%, OR=2.83, 95%CI: 0.51,
15.69 |
1 study with an overall low risk of bias |
50% of eligible studies and 71% of participants had
usable data |
0% studies and 0% participants with schizophrenia |
No clear indication of other biases |
| 19 |
TAAR1 agonists vs. antipsychotics in any eligible
population |
Dropouts due to adverse events |
4 weeks |
N=1 n=214; 6.4% vs. 1.4%, OR=5.02, 95%CI: 0.62,
40.38 |
1 study with an overall low risk of bias |
16.7% of eligible studies and 13.8% of participants had
usable data |
No clear indication of indirectness |
No clear indication of other biases |
| 21 |
TAAR1 agonists vs. antipsychotics in any eligible
population |
Dropouts due to adverse events |
1 day |
N=1 n=71; not estimable effect size 0 events in both
arms |
1 study with an overall low risk of bias |
50% of eligible studies and 71% of participants had
usable data |
0% studies and 0% participants with schizophrenia |
No clear indication of other biases |
| 23 |
TAAR1 agonists vs. antipsychotics in any eligible
population |
Any adverse event |
4 weeks |
N=1 n=214; 26.5% vs. 48.6%, OR=0.38, 95%CI: 0.21,
0.68 |
1 study with an overall low risk of bias |
16.7% of eligible studies and 13.8% of participants had
usable data |
No clear indication of indirectness |
No clear indication of other biases |
| 25 |
TAAR1 agonists vs. antipsychotics in any eligible
population |
Any adverse event |
1 day |
N=1 n=71; 97.1% vs. 41.7%, OR=47.6, 95%CI: 5.85,
387.2 |
1 study with an overall low risk of bias |
50% of eligible studies and 71% of participants had
usable data |
0% studies and 0% participants with schizophrenia |
No clear indication of other biases |
| 66 |
TAAR1 agonists vs. antipsychotics in any eligible
population |
Serious adverse events |
4 weeks |
N=1 n=214; 2.5% vs. 0.7%, OR=3.79, 95%CI: 0.19,
74.42 |
1 study with an overall low risk of bias |
16.7% of eligible studies and 13.8% of participants had
usable data |
No clear indication of indirectness |
No clear indication of other biases |
| 68 |
TAAR1 agonists vs. antipsychotics in any eligible
population |
Serious adverse events |
1 day |
N=1 n=71; 4.2% vs. 1.4%, OR=3.17, 95%CI: 0.13,
80.58 |
1 study with an overall low risk of bias |
50% of eligible studies and 71% of participants had
usable data |
0% studies and 0% participants with schizophrenia |
No clear indication of other biases |
| 62 |
TAAR1 agonists vs. antipsychotics in any eligible
population |
Mortality due to any cause |
4 weeks |
N=1 n=214; not estimable effect size 0 events in both
arms |
1 study with an overall low risk of bias |
16.7% of eligible studies and 13.8% of participants had
usable data |
No clear indication of indirectness |
No clear indication of other biases |
| 64 |
TAAR1 agonists vs. antipsychotics in any eligible
population |
Mortality due to any cause |
1 day |
N=1 n=71; not estimable effect size 0 events in both
arms |
1 study with an overall low risk of bias |
50% of eligible studies and 71% of participants had
usable data |
0% studies and 0% participants with schizophrenia |
No clear indication of other biases |
| 46 |
TAAR1 agonists vs. antipsychotics in any eligible
population |
Nausea/vomitting |
4 weeks |
N=1 n=214; 1.4% vs. 8.1%, OR=0.16, 95%CI: 0.03,
0.84 |
1 study with an overall low risk of bias |
16.7% of eligible studies and 13.8% of participants had
usable data |
No clear indication of indirectness |
No clear indication of other biases |
| 48 |
TAAR1 agonists vs. antipsychotics in any eligible
population |
Nausea/vomitting |
1 day |
N=1 n=71; 34.7% vs. 1.4%, OR=38.83, 95%CI: 2.19,
687.51 |
1 study with an overall low risk of bias |
50% of eligible studies and 71% of participants had
usable data |
0% studies and 0% participants with schizophrenia |
No clear indication of other biases |
| 60 |
TAAR1 agonists vs. antipsychotics in any eligible
population |
Weight increased (≥7% increase or any cutoff) |
4 weeks |
N=1 n=214; 1.4% vs. 10.8%, OR=0.12, 95%CI: 0.02,
0.58 |
1 study with an overall low risk of bias |
16.7% of eligible studies and 13.8% of participants had
usable data |
No clear indication of indirectness |
No clear indication of other biases |
| 36 |
TAAR1 agonists vs. antipsychotics in any eligible
population |
Agitation |
4 weeks |
N=1 n=214; 6% vs. 0.7%, OR=9.56, 95%CI: 0.54,
167.96 |
1 study with an overall low risk of bias |
16.7% of eligible studies and 13.8% of participants had
usable data |
No clear indication of indirectness |
No clear indication of other biases |
| 32 |
TAAR1 agonists vs. antipsychotics in any eligible
population |
Anxiety |
4 weeks |
N=1 n=214; 3.6% vs. 6.8%, OR=0.51, 95%CI: 0.14,
1.83 |
1 study with an overall low risk of bias |
16.7% of eligible studies and 13.8% of participants had
usable data |
No clear indication of indirectness |
No clear indication of other biases |
| 34 |
TAAR1 agonists vs. antipsychotics in any eligible
population |
Anxiety |
1 day |
N=1 n=71; 1.2% vs. 8.3%, OR=0.13, 95%CI: 0.01,
2.71 |
1 study with an overall low risk of bias |
50% of eligible studies and 71% of participants had
usable data |
0% studies and 0% participants with schizophrenia |
No clear indication of other biases |
| 51 |
TAAR1 agonists vs. antipsychotics in any eligible
population |
Sedation |
1 day |
N=1 n=71; 60% vs. 13.9%, OR=9.3, 95%CI: 2.91,
29.72 |
1 study with an overall low risk of bias |
50% of eligible studies and 71% of participants had
usable data |
0% studies and 0% participants with schizophrenia |
No clear indication of other biases |
| 56 |
TAAR1 agonists vs. antipsychotics in any eligible
population |
Insomnia |
4 weeks |
N=1 n=214; 5.7% vs. 6.8%, OR=0.84, 95%CI: 0.26,
2.65 |
1 study with an overall low risk of bias |
16.7% of eligible studies and 13.8% of participants had
usable data |
No clear indication of indirectness |
No clear indication of other biases |
| 38 |
TAAR1 agonists vs. antipsychotics in any eligible
population |
Headache |
4 weeks |
N=1 n=214; 6.4% vs. 8.1%, OR=0.78, 95%CI: 0.27,
2.28 |
1 study with an overall low risk of bias |
16.7% of eligible studies and 13.8% of participants had
usable data |
No clear indication of indirectness |
No clear indication of other biases |
| 40 |
TAAR1 agonists vs. antipsychotics in any eligible
population |
Headache |
1 day |
N=1 n=71; 11.4% vs. 2.8%, OR=4.52, 95%CI: 0.48,
42.59 |
1 study with an overall low risk of bias |
50% of eligible studies and 71% of participants had
usable data |
0% studies and 0% participants with schizophrenia |
No clear indication of other biases |
| 44 |
TAAR1 agonists vs. antipsychotics in any eligible
population |
Dizziness |
1 day |
N=1 n=71; 28.6% vs. 2.8%, OR=14, 95%CI: 1.68,
116.49 |
1 study with an overall low risk of bias |
50% of eligible studies and 71% of participants had
usable data |
0% studies and 0% participants with schizophrenia |
No clear indication of other biases |
| 30 |
TAAR1 agonists vs. antipsychotics in any eligible
population |
Anticholinergic symptom |
1 day |
N=1 n=71; 15.3% vs. 1.4%, OR=13.16, 95%CI: 0.7,
247.71 |
1 study with an overall low risk of bias |
50% of eligible studies and 71% of participants had
usable data |
0% studies and 0% participants with schizophrenia |
No clear indication of other biases |